Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T22:39:03.215Z.
Calculation as of: 2026-10-06T22:39:03.215Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a58e0fcb5c5c5211a6c4e1a8bb78ffa34e5085398ec1b7e8aba4a6f7bffe7660
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Unicycive Therapeutics, Inc.
Market Cap
$112.94M
EV/EBITDA Ratio
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO |
|---|---|---|
| Unicycive Therapeutics, Inc. (UNCY) | $112.94M | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $112.57M | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $113.77M | N/A |
| Genelux Corporation (GNLX)vs › | $113.89M | N/A |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.46M | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $110.30M | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $115.67M | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $109.14M | N/A |
| MaxCyte, Inc. (MXCT)vs › | $116.76M | N/A |
| Spruce Biosciences, Inc. (SPRB)vs › | $117.76M | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
